Following injection, the animal should be allowed to rest of agitation. The pharmacological response elicited by medetomidine, a 2-adrenergic agonist, is a potent α2-agonist, is indicated for the induction of surgical anaesthesia in dogs. 

**Clinical pharmacology:** CEPETOR® is a non-narcotic sedative and analgesic drug, a α2-agonist, which produces sedation and analgesia. These effects are dose dependent in depth and duration of sedative/analgesic effects ranging with the following conditions: cardiac disease, respiratory are severely debilitated, or dogs which are stressed due to extreme heat, cold or fatigue.

**Rebound of adverse reactions are listed in decreasing order of seriousness. It should also be noted that suspected adverse drug reactions should be reported to the manufacturer. The categories of adverse reactions are listed in decreasing order of frequency by body system.**

**Toxinological:** CNS depression, seizures in 2-10 minutes after initial dose.

**Precautions for use:** Although all adverse reactions are not reported, the following adverse reaction information is based on voluntary post-approval drug experience reporting. It is generally recognized that this method of reporting results in a significant under-reporting of adverse reactions. It should also be noted that suspected adverse drug reactions listed here reflect reporting and not causality. The categories of adverse reactions are listed in decreasing order of frequency by body system.**

**Storage:** Store at controlled room temperature 15-30°C. Protect from freezing.

**Presentation:** CEPETOR® is supplied in 5 mL multidose vials containing 1.5 mg of medetomidine hydrochloride per mL.